APA (7th ed.) Citation

Zhou, C., Xiong, A., Zhao, J., Li, W., Bi, M., Chen, J., . . . Liu, Z. (2022). 7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial. Annals of Oncology, 33, S31. https://doi.org/10.1016/j.annonc.2022.02.016

Chicago Style (17th ed.) Citation

Zhou, C., et al. "7MO Oritinib (SH-1028) a Third-generation EGFR Tyrosine Kinase Inhibitor in Locally Advanced or Metastatic NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase II Trial." Annals of Oncology 33 (2022): S31. https://doi.org/10.1016/j.annonc.2022.02.016.

MLA (9th ed.) Citation

Zhou, C., et al. "7MO Oritinib (SH-1028) a Third-generation EGFR Tyrosine Kinase Inhibitor in Locally Advanced or Metastatic NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase II Trial." Annals of Oncology, vol. 33, 2022, p. S31, https://doi.org/10.1016/j.annonc.2022.02.016.